Additional file 1 of Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients

Abrao, Mauricio S., Surrey, Eric, Gordon, Keith, Snabes, Michael C., Wang, Hui, Ijacu, Horia, Taylor, Hugh S.
2021 · doi:10.6084/m9.figshare.14795093 · W6920961273
article OA: green CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-11 ⓘ

This paper presents supplemental tables and figures detailing elagolix's consistent efficacy in reducing endometriosis-associated pain across various patient subgroups and its safety profile.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Additional file 1: Supplemental Table 1. Endometriosis Health Profile-30 at month 3 – pain; Supplemental Table 2. Endometriosis Health Profile-30 at month 3 – control and powerlessness; Supplemental Table 3. Endometriosis Health Profile-30 at month 3 – emotional well-being; Supplemental Table 4. Endometriosis Health Profile-30 at month 3 – social support; Supplemental Table 5. Endometriosis Health Profile-30 at Month 3 – self-image; Supplemental Table 6. Endometriosis Health Profile-30 at month 3 – sexual intercourse; Supplemental Table 7. Adverse events from integrated Elaris EM-I and Elaris EM-II by selected subgroup; Supplemental Figure 1. Co-primary endpoints at month 3 for integrated Elaris EM-I and II by baseline demographic subgroups; Supplemental Figure 2. Co-primary endpoints at month 3 for integrated Elaris EM-I and Elaris EM-II by disease severity subgroups; Supplemental Figure 3. Patient Global Impression of Change (PGIC) at month 3 for integrated Elaris EM-I and Elaris EM-II by baseline demographic subgroups; Supplemental Figure 4. Patient Global Impression of Change (PGIC) at month 3 for integrated Elaris EM-I and Elaris EM-II by disease severity subgroups.

My notes (saved in your browser only)

Outcome instruments

EHP-30

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

Source provenance

openalex
last seen: 2026-05-11T08:33:45.119282+00:00
License: CC0 · commercial use OK